Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading activity on Tuesday. Investors acquired 23,660 call options on the stock. This is an increase of approximately 33% compared to the average daily volume of 17,739 call options.

Boston Scientific Stock Up 0.4%

BSX stock traded up $0.28 during trading on Tuesday, hitting $74.40. 9,601,702 shares of the company’s stock were exchanged, compared to its average volume of 17,176,426. The business has a 50-day moving average price of $92.85 and a two-hundred day moving average price of $98.47. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $110.30 billion, a price-to-earnings ratio of 38.35, a PEG ratio of 1.60 and a beta of 0.67. Boston Scientific has a 52-week low of $74.00 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the firm earned $0.70 EPS. The company’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts expect that Boston Scientific will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC increased its holdings in shares of Boston Scientific by 26.4% in the fourth quarter. Clear Harbor Asset Management LLC now owns 3,550 shares of the medical equipment provider’s stock valued at $338,000 after purchasing an additional 741 shares during the period. Hazlett Burt & Watson Inc. raised its stake in shares of Boston Scientific by 32.2% during the 4th quarter. Hazlett Burt & Watson Inc. now owns 1,013 shares of the medical equipment provider’s stock worth $98,000 after buying an additional 247 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its holdings in Boston Scientific by 3.0% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 906,900 shares of the medical equipment provider’s stock worth $86,473,000 after acquiring an additional 26,655 shares during the period. Parr Mcknight Wealth Management Group LLC boosted its position in shares of Boston Scientific by 3.7% during the 4th quarter. Parr Mcknight Wealth Management Group LLC now owns 26,371 shares of the medical equipment provider’s stock worth $2,514,000 after purchasing an additional 938 shares in the last quarter. Finally, MUFG Securities EMEA plc grew its position in Boston Scientific by 1,096.8% during the fourth quarter. MUFG Securities EMEA plc now owns 339,427 shares of the medical equipment provider’s stock worth $32,364,000 after buying an additional 311,065 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on BSX. Royal Bank Of Canada decreased their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. The Goldman Sachs Group set a $99.00 price objective on shares of Boston Scientific in a report on Thursday. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday. Mizuho cut their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Canaccord Genuity Group decreased their target price on Boston Scientific from $131.00 to $112.00 and set a “buy” rating for the company in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $109.43.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.